Seeking Alpha

Oncolytics Biotech (ONCY) -13.4% premarket after saying it will expand enrollment in its Phase...

Oncolytics Biotech (ONCY) -13.4% premarket after saying it will expand enrollment in its Phase III study of Reolysin, a possible treatment for head and neck cancers, after observing different responses in two different groups of patients.
Comments (1)
  • this could be positive
    14 Sep 2012, 10:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)